Acute Myeloid Leukemia Diagnosis and Risk Assessment

Definition and Risk Stratification

• Acute promyelocytic leukemia (APL) with a WBC count >10 × 10⁹/L is considered high-risk disease, according to the European Society for Medical Oncology 1
• Induction chemotherapy with cytarabine plus anthracycline is recommended for Acute Myeloid Leukemia (AML) patients, with standard induction including cytarabine (100-200 mg/m² continuous infusion × 7 days) plus anthracycline (idarubicin 12 mg/m² or daunorubicin 45-60 mg/m² × 3 days), as recommended by the European Society for Medical Oncology 2, 3

Initial Management

• All-trans retinoic acid (ATRA) should be started immediately when Acute Promyelocytic Leukemia (APL) is suspected, and chemotherapy should be added if white blood cell count is greater than 10 × 10⁹/L, as recommended by the American Society of Hematology 4, 5
• Options for cytoreduction in APL patients include idarubicin, gemtuzumab ozogamicin, and hydroxyurea, with dosages of 12 mg/m², 6-9 mg/m², and 2-4 g per day, respectively 4
• Prophylactic steroids, such as dexamethasone, should be considered to prevent differentiation syndrome in APL patients 4, 5
• Aggressive intravenous hydration, hydroxyurea, and prevention of tumor lysis syndrome should be initiated for hyperleukocytosis (white blood cell count >100 × 10⁹/L) 1

Cytoreduction Methods

Leukapheresis and Leukostasis

• Leukapheresis is contraindicated in APL patients due to the risk of fatal hemorrhage, but may be considered for patients with leukostasis, with prompt initiation of definitive chemotherapy based on the underlying leukemia type 5, 3
• Patients with leukostasis should be treated with rapid cytoreduction through leukapheresis and/or hydroxyurea, followed by prompt initiation of definitive chemotherapy 3

Diagnostic Evaluation

• Bone marrow aspiration is essential when leukemia is suspected, as up to 20% of patients with acute leukemia lack circulating blast cells at diagnosis, and should be performed under sterile conditions, with evaluation not delayed when leukemia is suspected, and performed within 2 weeks prior to treatment initiation 7, 8
• Flow cytometry for immunophenotyping is necessary for accurate diagnosis and risk-directed therapy in suspected leukemia, and genetic abnormalities should be assessed with cytogenetic techniques, including karyotyping and PCR for oncogene fusion transcripts 7

Monitoring and Supportive Care

• Regular CBC monitoring is essential, with frequency depending on severity and cause, as stated by the European Society for Medical Oncology, and febrile neutropenia is a medical emergency requiring immediate intervention, including broad-spectrum antibiotics, as recommended by the Infectious Diseases Society of America 9, 10
• Platelet transfusions are recommended if count ≤10 × 10⁹/L or 10-20 × 10⁹/L with fever or infection, as recommended by the American Society of Hematology and the American Association of Blood Banks 11, 12, 4, 13
• Oral iron supplementation should be initiated for confirmed iron deficiency, with typical dosing of ferrous sulfate 325 mg (65 mg elemental iron) 1-3 times daily, and monitoring hemoglobin and MCHC response after 4-6 weeks, as recommended by the American College of Physicians 14

Referral and Treatment Decisions

• Referral to hematology for specialized management may be required for suspected primary bone marrow disorders, according to the National Comprehensive Cancer Network and the International Society for Experimental Hematology 3, 11
• Treatment decisions should be based on symptoms, rate of increase, and underlying leukemia type, as stated by the American Society of Clinical Oncology, European Society for Medical Oncology, and National Comprehensive Cancer Network, and treatment should not be delayed once the diagnosis is established and initial cytoreduction has been achieved 15, 16, 17, 2